Auburn U, Gen9, Autodesk Collaborate on Synthetic Oncolytic Virus to Treat Cancer in Dogs | GenomeWeb

NEW YORK (GenomeWeb) – A collaboration between a veterinary oncologist, synthetic DNA manufacturer Gen9, and design software firm Autodesk claims to have created the largest synthetic viral genome to date, which will be used in clinical trials to treat cancer in dogs using oncolytic viruses.

The synthetic canine adenovirus Type 2 (CAV-2) genome measures between 32 and 33 kilobases, a record, based on a recent literature search, Gen9 VP of Research and Development Devin Leake told GenomeWeb. He noted that several synthetized bacterial genomes have been larger.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.

Mar
23
Sponsored by
Personal Genome Diagnostics

This webinar will discuss genomic methods to elucidate the molecular mechanisms underlying acquired resistance to immuno-oncology (IO) therapies.

Mar
28

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment.